Abstract Marijuana cannabinoid treatment increases Th2 activity, and previous reports showed that B cells express the highest level of CB 2 mRNA relative to other immune cells, suggesting that cannabinoids play a critical role in B cell activation and maturation. We previously reported evidence of Th2 biasing and class switching in cannabinoid-treated and antigen-challenged mice. We now explore the possibility that cannabinoids directly influence B cell antibody class switching. Mouse splenic B cells were purified by negative selection and cultured with IL4 and anti-CD40 in the presence or absence of the nonselective cannabinoid agonist, CP55940, or the CB 1 selective cannabinoid agonist, methanandamide, and analyzed at different days by flow cytometry for surface expression of either IgM or IgE. Cells treated with CP55940 showed an increase in expression of IgE by day 5 in culture; methanandamide had no effect. CP55940 also induced an increase in secreted IgE in culture supernatants as analyzed by ELISA. In addition, CB 2 receptors were increased on B cells after stimulation with IL-4 and anti-CD40, and the class switching effect of CP55940 was attenuated by the CB 2 antagonist, SR144528. These results suggest that cannabinoids bias toward Th2-type immunity by directly inducing B cell class switching from IgM to IgE through a mechanism involving CB 2 receptors.
Introduction
Cannabinoid receptors and ligands have been reported to be produced in cells of the immune system and to regulate immune cell function with immune suppression being a dominant response (Klein 2005; Klein and Cabral 2006) . B lymphocytes express an abundance of CB 2 message relative to other immune cells (Carayon et al. 1998; Lee et al. 2001) , and cannabinoids have been shown to increase B cell function rather than suppress it. For example, proliferation of B cells was reported to be increased by cannabinoid agonists (Carayon et al. 1998) , CB 2 receptors were reported to be increased after IL-4 treatment (Lee et al. 2001) , and Th2-type antibody responses to Legionella pneumophila were increased in THC-treated and immune stimulated mice (Newton et al. 1994 ). In addition, cannabinoids have been reported to polarize toward Th2 immunity in a variety of models and at least a portion of this effect is because of a modulation of T helper cytokines produced by dendritic cells and T cells (Lu et al. 2006) . Th2 cytokines such as IL-4 stimulate B cells to undergo immunoglobulin (Ig) heavy chain class switching and thus induce these cells to produce IgE and IgG1 rather than IgM and IgG2a (Takeda et al. 1996) . Because we had observed that cannabinoids increased IgG1 and not IgG2a antibodies (Newton et al. 1994) and because IL-4 activity is reported to promote the expression of CB 2 mRNA in B cells (Schroder et al. 2002) , we examined the possibility that cannabinoids act on B cells directly to induce Ig class switching through a CB 2 -mediated mechanism. The results show that the nonselective, full cannabinoid agonist, CP55940, increased IgE class switching in cultures of mouse, splenic B cells whereas the CB 1 selective agonist, methanandamide, had no effect. In addition, CB 2 receptors were increased on B cells after stimulation with IL-4 and anti-CD40 antibodies, and the class switching effect of CP55940 was attenuated by the CB 2 antagonist, SR144528. These results suggest that cannabinoids bias toward Th2-type immunity by directly inducing B cell class switching from IgM to IgE through a mechanism involving CB 2 receptors.
Materials and methods
Mice and drugs C57BL/6 mice, 6-12 weeks of age, were obtained from CB 2 breeding colony housed and cared for at the University of South Florida Health Science Center animal facility, which is fully accredited by the American Association for Accreditation of Laboratory Animal Care. (Klein et al. 2003) . CP55940 was first diluted in 95% ethanol to a concentration of 100 mM and then in 10% fetal calf serum-RPMI 1640 medium to a working concentration of 100 μM. Methanandamide was diluted in ethanol to a concentration of 5 mg/ml and then in 10% fetal calf serum-RPMI 1640 medium to a working concentration of 140 μM. SR141716A and SR144528 were obtained from the Research Technology Branch of the National Institute on Drug Abuse (Rockville, MD, USA) and were first diluted in 95% ethanol to 20 mg/ml and then in 10% fetal calf serum-RPMI 1640 medium to a working concentration of 20 μg/ml.
Preparation of purified B lymphocytes Spleens were collected from C57BL/6 male and female mice at 6 to 12 weeks of age and processed in a Stomacher™ 80 lab blender for single cell suspensions. B cells were enriched by magnetic negative selection (EasySep™ from StemCell Technologies). Isolated B cells were cultured in six-well culture plates (Corning Life sciences, Acton, MA, USA) at a concentration of 5.0×10 5 cells/ml in RPMI 1640 medium supplemented with 5 μM 2-mercaptoethanol, 2 mM L-glutamine, 1% antibiotic/antimycotic solution (Sigma, St. Louis, MO, USA), 10% heat-inactivated fetal calf serum (Hyclone; Logan, UT, USA), 0.1-10 ng/ml recombinant IL-4 (BD Bioscience PharMingen, San Jose, CA, USA), and 500 ng/ml purified hamster anti-mouse CD40 (BD Bioscience PharMingen). The medium and reagents were replenished every 48 h. B cells were harvested after 5 days in culture and the purity of the cells was determined by flow cytometry staining using fluorochrome-conjugated monoclonal antibodies (mAbs) to CD19 and CD45R/B220 (BD Bioscience PharMingen). The B cell purity was greater than 98% as analyzed by flow Cytometry on a BD Canto II (BD Bioscience).
Treatment of purified B lymphocytes B cell cultures were stimulated with IL-4 (0.1 ng/ml) and anti-CD40 (500 ng/ml), and different experimental groups were set up. Stimulated B cells were treated with the CB 1 receptor agonist, methanandamide (0.5 or 1 μM); the receptor nonselective agonist, CP55940 (0.5 or 1 μM); or equivalent concentrations of drug diluent, ethanol (ETOH, vehicle control) . In studies with antagonists, B cells were pretreated with the CB 1 antagonist, SR141716A (0.1 μM) or the CB 2 antagonist, SR144528 (0.1 μM) for 30 min before CP55940 treatment. B cells were cultured for 5 days followed by flow cytometry and ELISA analysis.
Cell surface marker analysis by flow cytometry B cell purity was assessed by flow cytometry staining using fluorochromeconjugated mAbs to CD19 and CD45R/B220 (BD Bioscience PharMingen). To evaluate the effects of CP55940 and methanandamide on purified B cells, the treated and untreated cells were harvested after 5 days in culture. Intracellular CB 2 receptor analysis by flow cytometry To assess the levels of CB 2 protein in unstimulated and stimulated B cells, the cells were fluorescent stained before (day 0) and after (day 5) stimulation. Cells were then blocked with mouse Fc block (CD16/CD32) and normal goat serum (Chemicon International, Temecula, CA, USA). To stain the CB 2 receptor, the cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD Bioscience) to allow the antibody to enter the cell and bind the peptide mapping to the C terminus of the mouse CB 2 receptor. Intracellular and surface CB 2 receptor was stained indirectly in the permeabilized cells with goat anti-mouse CB 2 as primary antibody and FITC-conjugated donkey antigoat IgG as secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). According to the manufacturer, the anti-CB 2 antibody is raised to a 15-20 amino acid peptide within the last 50 amino acids of the C terminus. Cells were incubated for 30 min on ice with both antibodies, washed, and resuspended in PBS containing 2% fetal calf serum. Cells were acquired on a BD Calibur or BD Canto II and analyzed by Cellquest or Flowjo software.
Detection of secreted IgE in culture supernatants by ELISA To assess IgE secretion, B cells were stimulated with 0.1 ng/ml recombinant IL-4 and 500 ng/ml anti-CD40, and treated with the CB 1 receptor agonist, methanandamide (0.5 and 1 μM); the nonselective agonist, CP55940 (0.5 and 1 μM); or equivalent concentrations of drug diluent, ethanol (ETOH, vehicle control). Supernatants from B cell cultures were collected at 5 days post treatment, and the levels of secreted IgE in supernatants were measured using BD OptEIA kit (BD Bioscience PharMingen). Ninety-six-well enzyme immunoassay plates (Corning Life Science) were coated with 50 μl of anti-mouse IgE (100 ng/ml) in 0.1 M NaHCO 3 , pH 9.5, overnight at 4°C. The wells were blocked with 150 μl of 0.5% bovine serum albumin/0.05% Tween 20 in PBS for 1 h at 37°C. B cell supernatants from cannabinoid treated and untreated cultures or serial dilutions of IgE standards were added and incubated for 2 h at 37°C followed by biotinylated detection antibody and streptavidin-horseradish peroxidase (1:250 in 50 μl) for 1 h at 37°. The wells were washed between each addition. Tetramethyl benzidine (Sigma) substrate was added to the wells and allowed to develop at room temperature for 5-10 min. The reaction was on an E max microplate reader (Molecular Devices; Menlo Park, CA, USA). The concentrations of secreted IgE were calculated from standard curves that were done for each plate.
Cell viability To assess cell viability, cells were cultured as previously described and stained with 7-amino-actinomycin D (7-AAD) (BD Pharmingen). Viable cells (7-AAD negative) and dead cells (7-AAD positive) were quantitated by flow cytometry.
Statistical analysis Comparisons between groups were performed using the two-tailed Student's t test. A value of p<0.05 was indicative of significance.
Results
Splenic B cell phenotype Because cannabinoid receptors have been shown to play an important role in B cell biology, we used primary B cells as our model to study cannabinoid effects and CB 2 receptor expression. As previously described, primary cultures of mouse B cells can be induced to proliferate and undergo Ig class switching to IgG1 and IgE under the influence of added anti-CD40 antibody and recombinant IL-4 (Rush et al. 2002) . Before testing cannabinoid effects on primary B cells, the cell phenotype was analyzed at different time points in culture. The results in Fig. 1a show the scatter characteristics of primary unstimulated B cells at day 0 and stimulated B cells after 5 days in culture with recombinant IL-4 and anti-CD40. After enrichment, these B cells are >98% CD19 positive, IgE negative, and nearly 100% viable. Viability studies as measured using 7-amino-actinomycin D (7-AAD) showed that gated CD19 positive B cells were 98% viable at days 0 and 5. B cell characteristics change as the cells are cultured with IL-4 and anti-CD40. At low concentrations of IL-4 (0.1 ng/ml), switching to surface IgE expression occurs at a relatively low level (3%). As the concentration of IL-4 is increased (10 ng/ml), IgE surface expression increased dramatically (97%), as shown in Fig. 1b . To further analyze B cell characteristics, surface staining for B cell activation markers was performed. Figure 2 shows unstimulated B cells were CD19, CD45, and MHCII positive, and they expressed low levels of CD80 and were about 80% positive for CD23. After 5 days in culture, all markers remained the same with the exception of CD23 expression, which was decreased substantially to around 40% positive. CD23 is a low-affinity receptor for IgE, and the significance of the drop in expression of this protein is unclear at this time.
CB 2 receptor expression on B cells Previous studies showed that among immune cell subtypes, B cells express the highest level of CB 2 mRNA (Galieque et al. 1995; Lee et al. 2001 ). In the current report, B cells were stimulated in culture for 5 days and then harvested, fixed, permeabilized with BD Cytofix/Cytoperm solution, and analyzed for CB 2 protein by flow cytometry using indirect labeling with antibodies to the carboxy end of the receptor. The results show that CB 2 protein expression on B cells changed with B cell activation by IL-4 and anti-CD40 (Fig. 3a) . CB 2 protein expression was very low in unstimulated cells, however, the expression increased substantially after stimulation with IL-4 and anti-CD40. There was also a tenfold difference in the mean fluorescence intensity (MFI) per cell between unstimulated and stimulated cells (Fig. 3b) . The antibodies used in this study are specific for a CB 2 peptide and, therefore, these results suggest that IL-4 and anti-CD40 can dramatically increase the expression of specific immunoreactive protein on B cells.
CP55940 enhances class switching from IgM to IgE
To date no studies have been reported on the effects of cannabinoids on B cell immunoglobulin class switching. Therefore, in the current study, we examined the direct effect of the cannabinoid agonists on class switching from IgM to IgE in B cell cultures. B cells were stimulated in culture with IL-4 (0.1 ng/ml) and anti-CD40 (500 ng/ml), then treated with 0.5 μM or 1 μM CP55940 or methanandamide (Fig. 4) . Cells from the control group were untreated, and vehicle control group was treated with equivalent amounts of ethanol. All cells were harvested at day 5 and two-color stained with anti-CD19-PE and antiIgE-FITC. CD19+ IgE+ B cells were gated and analyzed by flow cytometry. Only B cells treated with CP55940 were shown to have an increase in expression of surface IgE by day 5; treatment with 0.5 μM CP55940 showed a twofold increase in surface IgE, whereas treatment with 1 μM CP55940 showed a threefold increase in surface IgE. in initial studies, had no effect at concentrations ranging from 0.1 to 10 μM (data not shown). These results show that the nonselective agonist, CP55940, but not the CB 1 agonist, methanandamide, directly enhances IgE surface expression on B cells after 5 days of stimulation with IL-4 and anti-CD40.
CP55940 enhances IgE secretion
Besides enhancing IgE surface expression, CP55940 was also shown to enhance IgE secretion into culture supernatants. B cells were stimulated in culture with IL-4 and anti-CD40 and two different concentrations of CP55940 or methanandamide as described above. Untreated control cells and vehicle-treated cells were also studied. All cells were harvested at day 5, and supernatants were collected for IgE analysis by ELISA (Fig. 5 ). Cultures treated with 0.5 μM CP55940 showed a 15-fold increase in IgE levels (approximately 5,000 ng/ml) compared to vehicle control. One-micromolar CP55940-treated cultures showed a fivefold increased in IgE levels (approximately 2,500 ng/ml) compared to the vehicle control. We did not observe a concentration-dependent increase in IgE secretion. This may be because of the rate of degradation and the half-life of unbound IgE in culture. Methanandamide had very little effect in IgE secretion similar to untreated and vehicle controls. Overall, only cultures treated with CP55940 enhanced IgE secretion by day 5.
CB 2 antagonist attenuates CP55940 effect The above data show that the nonselective agonist CP55940 enhanced IgE surface expression and secretion in B cell cultures. On the other hand, the CB 1 selective agonist, methanandamide, had no effect on B cell class switching. Therefore, we suspected that the CB 2 receptors were involved in the class switching effect observed when B cells were treated with CP55940. To confirm CB 2 involvement, B cells were treated with CB 1 or CB 2 antagonists before CP55940 treatment. Cells were stimulated as above with IL-4 and anti-CD40 and then pretreated with the CB 1 antagonist, SR141716A or the CB 2 antagonist, SR144528 (0.1 μM) for 30 min before CP55940 (0.5 μM) treatment. Controls were treated with either antagonist only. The data showed CB 2 receptor involvement in that pretreatment with the CB 2 antagonist attenuated the CP55940 effect to a greater extent than pretreatment with the CB 1 antagonist (Fig. 6) . Clearly, more studies are needed, but these data suggest a more robust role of CB 2 in the regulation of class switching. were stimulated with IL-4 (0.1 ng/ml) and anti-CD40 (500 ng/ml) with or without drug treatment for 5 days. Cells were treated with either 0.5 or 1 μM CP55940 or methanandamide, and supernatants were collected at day 5 and analyzed for IgE by ELISA. Y-axis represents the secreted IgE levels in ng/ml. Data are presented as the mean IgE ng/ml±SEM for three individual experiments using B cell culture supernatants from different B cell treatments. *p<0.05, t test for CP55940-treated cells versus the respective vehicle (EtOH) controls Discussion CB 2 receptors are expressed more abundantly in the immune system than CB 1 ; however, the role of these receptors is still not clear in both the normal functioning of the immune system and in the immunomodulation effect of cannabinoid-based drugs (Klein 2005; Klein and Cabral 2006) . The role of these receptors in B cell biology has been of particular interest to us because these cells express the highest level of CB 2 mRNA among immune cells (Galieque et al. 1995) , have been shown to be activated by cannabinoids (Carayon et al. 1998) , and CB 2 message is increased in B cells by IL-4, the potent B cell activating cytokine (Schroder et al. 2002) . It is also known that immune cells produce endocannabinoids that bind to CB 2 receptors (Klein and Cabral 2006) ; therefore, it is possible that during immune activation, these endogenous ligands might modulate B cell function such as immunoglobulin class switching. It is possible that the effect we have observed in the current study with CP55940 is strongly mimicking the natural CB 2 augmentation of class switching induced by endogenous cannabinoid ligands. Primary cultures of mouse B cells can be induced to proliferate and undergo Ig class switching to IgG1 and IgE under the influence of added anti-CD40 antibody and recombinant IL-4 (Rush et al. 2002) . The IL-4 is the main stimulus of class switching because it induces the transcription of all germline genes as well as the ɛ germline gene leading to the production of IgE (Takhar et al. 2005) . Our results show that the degree of IgE class switching is dependent on the concentration of IL-4 added to the cultures and not on the concentration of anti-CD40, confirming the important role of this cytokine in class switching in highly purified B cell populations. The cultures treated with IL-4 and anti-CD40 also showed a robust increase in the expression of CB 2 protein as measured by flow cytometry. The method used detects both membrane bound and intracellular CB 2 protein so the absolute amount of protein expressed on the plasma membranes is not clear. However, preliminary studies (not shown) with antibodies directed to the external amino end of CB 2 and employing surface staining techniques suggest that the level of membrane expression is quite low relative to the total amount of protein expressed by the cell. Although several previous studies reported that IL-4-stimulated (Schroder et al. 2002) or anti-CD40 stimulated (Carayon et al. 1998; Lee et al. 2001 ) B cells increased CB 2 mRNA, our results are the first to show that mouse B cells stimulated with both agents also increase the expression of CB 2 protein. We are currently testing if IL-4 is a major stimulus in upregulating CB 2 protein as the previous studies measuring mRNA suggested (Schroder et al. 2002) . Cannabinoids such as THC have been reported to either suppress (Kaminski et al. 1994) or enhance (Newton et al. 1994 ) B cell functions such as antibody formation; however, these studies were done using mixed immune cell populations and, therefore, the direct effect of the drug on isolated B cells could not be determined. The current report is the first to examine cannabinoid effects on purified B cell populations, and the results show that the nonselective cannabinoid, CP55940, enhances the IL-4-and anti-CD40-induced class switching event so that by 5 days in culture the drug increased IgE expression by 40-60%. CP55940 is a nonselective agonist binding equally to both CB 1 and CB 2 . It is interesting to note that the results with the CB 1 selective agonist, methanandamide, showed no augmentation of class switching. This finding coupled with our data showing the CP55940 effect was attenuated to a greater extent by the CB 2 antagonist suggests that CB 2 is mediating the class switching effect. B cells in response to IL-4 and anti-CD40 undergo class switch recombination (CSR) changing the C region of the H chain to express IgE (Takhar et al. 2005) . The molecular mechanisms for CSR involve nonhomologous recombination in the switching sites of the H chain genes as well as the upregulation of the enzyme, activation-induced cytidine deaminase (AID). Our data suggest that the activation of CB 2 enhances IgE expression but it is not clear if this is through an increase in IL-4 production by the B cells or through an increase in the molecular events surrounding CSR. CB 2 is coupled predominantly through Gi/o proteins, i.e., negatively through the Gα subunit to adenylyl cyclase and positively through Gβ/γ to MAP kinase (Pertwee 2006 ). In addition, at least for CB 1 , there is some evidence that cannabinoid receptors may signal through Gs (Pertwee 2006) . From this, it is possible that these G protein-coupled mechanisms mediate either CSR as has been observed with other agents that increase cAMP (Roper et al. 1995) or affect IL-4 production as has been observed in the case of other cytokines such as IL-12 (Braun and Kelsall 2001) . We are currently examining the effect of cannabinoids on IL-4 mRNA expression in treated B cells as well as studying the effect of the drugs on AID production as a marker for increased CSR in B cells.
